Catalyst Total Assets from 2010 to 2024

CPRX Stock

USD 21.15 0.24 1.12%

Catalyst Pharmaceuticals Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2004-12-31

Previous Quarter

706.4 M

Current Value

772 M

Quarterly Volatility

168.3 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Total Assets Growth Pattern

Below is the plot of the Total Assets of Catalyst Pharmaceuticals over the last few years. Total assets refers to the total amount of Catalyst Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Catalyst Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Catalyst Pharmaceuticals' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 470.11 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Catalyst Total Assets Regression Statistics

	Arithmetic Mean	148,130,360
	Geometric Mean	53,117,325
	Coefficient Of Variation	114.39
	Mean Deviation	137,180,510
	Median	60,449,962
	Standard Deviation	169,450,237
	Sample Variance	28713.4T
	Range	493.5M
	R-Value	0.89
	Mean Square Error	6387.1T
	R-Squared	0.79
	Slope	33,750,903
	Total Sum of Squares	401987.4T

Catalyst Total Assets History

	2024	493.6 M
	2023	470.1 M
	2022	375.6 M
	2021	237.8 M
	2020	192.4 M
	2019	112.4 M
	2018	60.4 M

Other Fundumenentals of Catalyst Pharmaceuticals

Intangibles To Total Assets

Catalyst Pharmaceuticals Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Retained Earnings	Accounts Payable	Common Stock	Property Plant Equipment	Net Receivables	Net Tangible Assets	Short Term Investments	Capital Surpluse	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock	Current Deferred Revenue	Short Term Debt
Total Assets		1.0	-0.8	0.98	0.91	0.79	0.9	0.48	0.47	0.83	0.99	-0.5	0.68	0.89	0.75	0.51	0.81	-0.87	0.1
Total Stockholder Equity	1.0		-0.79	0.97	0.91	0.79	0.9	0.5	0.48	0.83	0.99	-0.49	0.69	0.89	0.75	0.51	0.81	-0.86	0.08
Net Debt	-0.8	-0.79		-0.79	-0.97	-0.52	-0.47	-0.61	-0.54	-0.35	-0.84	0.44	-0.74	-0.8	-0.95	0.09	-0.41	0.64	0.03
Total Liab	0.98	0.97	-0.79		0.9	0.81	0.88	0.42	0.39	0.82	0.96	-0.56	0.63	0.89	0.75	0.5	0.81	-0.92	0.18
Total Current Assets	0.91	0.91	-0.97	0.9		0.61	0.66	0.64	0.56	0.56	0.95	-0.41	0.79	0.86	0.91	0.13	0.58	-0.74	0.01
Retained Earnings	0.79	0.79	-0.52	0.81	0.61		0.75	-0.1	0.3	0.7	0.74	-0.72	0.15	0.79	0.63	0.62	0.75	-0.82	0.19
Accounts Payable	0.9	0.9	-0.47	0.88	0.66	0.75		0.33	0.25	0.97	0.85	-0.45	0.53	0.73	0.4	0.77	0.89	-0.81	0.11
Common Stock	0.48	0.5	-0.61	0.42	0.64	-0.1	0.33		0.37	0.28	0.55	0.23	0.95	0.45	0.4	-0.14	0.09	-0.23	-0.12
Property Plant Equipment	0.47	0.48	-0.54	0.39	0.56	0.3	0.25	0.37		0.2	0.53	-0.05	0.45	0.47	0.57	-0.06	0.19	-0.07	0.17
Net Receivables	0.83	0.83	-0.35	0.82	0.56	0.7	0.97	0.28	0.2		0.77	-0.37	0.46	0.65	0.29	0.86	0.87	-0.8	0.24
Net Tangible Assets	0.99	0.99	-0.84	0.96	0.95	0.74	0.85	0.55	0.53	0.77		-0.46	0.74	0.89	0.79	0.41	0.76	-0.81	0.03
Short Term Investments	-0.5	-0.49	0.44	-0.56	-0.41	-0.72	-0.45	0.23	-0.05	-0.37	-0.46		-0.03	-0.54	-0.49	-0.23	-0.48	0.57	-0.01
Capital Surpluse	0.68	0.69	-0.74	0.63	0.79	0.15	0.53	0.95	0.45	0.46	0.74	-0.03		0.66	0.54	0.02	0.27	-0.44	-0.08
Net Invested Capital	0.89	0.89	-0.8	0.89	0.86	0.79	0.73	0.45	0.47	0.65	0.89	-0.54	0.66		0.8	0.36	0.52	-0.8	0.14
Net Working Capital	0.75	0.75	-0.95	0.75	0.91	0.63	0.4	0.4	0.57	0.29	0.79	-0.49	0.54	0.8		-0.08	0.39	-0.63	0.02
Long Term Investments	0.51	0.51	0.09	0.5	0.13	0.62	0.77	-0.14	-0.06	0.86	0.41	-0.23	0.02	0.36	-0.08		0.73	-0.61	0.35
Capital Stock	0.81	0.81	-0.41	0.81	0.58	0.75	0.89	0.09	0.19	0.87	0.76	-0.48	0.27	0.52	0.39	0.73		-0.78	0.08
Current Deferred Revenue	-0.87	-0.86	0.64	-0.92	-0.74	-0.82	-0.81	-0.23	-0.07	-0.8	-0.81	0.57	-0.44	-0.8	-0.63	-0.61	-0.78		-0.25
Short Term Debt	0.1	0.08	0.03	0.18	0.01	0.19	0.11	-0.12	0.17	0.24	0.03	-0.01	-0.08	0.14	0.02	0.35	0.08	-0.25

Click cells to compare fundamentals

About Catalyst Pharmaceuticals Financial Statements

Catalyst Pharmaceuticals investors use historical fundamental indicators, such as Catalyst Pharmaceuticals' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	470.1 M	493.6 M
Intangibles To Total Assets	0.41	0.43

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC